1. Academic Validation
  2. Liposome-Encapsulated Rutin Attenuates Cisplatin-Induced Ototoxicity via Suppression of P53-Associated Oxidative Injury

Liposome-Encapsulated Rutin Attenuates Cisplatin-Induced Ototoxicity via Suppression of P53-Associated Oxidative Injury

  • Biomater Res. 2026 Feb 10:30:0324. doi: 10.34133/bmr.0324.
Bo Liu 1 2 3 Yaqin Tu 1 2 3 Xiangrui Li 1 2 3 Wenting Yu 1 2 3 Wenqing Zou 1 2 3 Wei Tang 1 2 3 Shimin Zong 1 2 3 Songwei Tan 4 Hongjun Xiao 1 2 3
Affiliations

Affiliations

  • 1 Department of Otorhinolaryngology-Head and Neck Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • 2 Institute of Otorhinolaryngology-Head and Neck Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • 3 Hubei Province Clinical Research Center for Deafness and Vertigo, Wuhan 430022, China.
  • 4 School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Abstract

Cisplatin (CDDP) is a widely used chemotherapeutic agent, but its clinical applications are constrained by ototoxic side effects. Currently, few effective strategies exist to prevent or mitigate CDDP-induced ototoxicity. Rutin is known for its cell-protective effects by reducing oxidative stress and inhibiting Apoptosis. However, its limited water solubility and inefficient delivery to the inner ear pose substantial challenges. To address this, rutin is encapsulated in liposomes (Lip-Rutin) for nanoscale drug delivery, leveraging its antioxidant properties. Lip-Rutin markedly attenuates CDDP-induced oxidative stress damage and Apoptosis, demonstrating a protective effect on OC-1 cells. The efficacy of Lip-Rutin in safeguarding against CDDP-induced ototoxicity is further validated through in vivo studies. Consequently, Lip-Rutin emerges as a promising novel therapeutic agent for combating CDDP-induced ototoxicity.

Figures
Products
Inhibitors & Agonists
Other Products